Moderna, Inc. (MRNA)
Treasure Hunt: 3 Biotech Stocks Wall Street Hasn't Discovered Yet
Searching for quality undiscovered biotech stocks can be a bit like a treasure hunt. The biotech scene is full of intriguing innovators trying to progress their treatments through various clinical trials.
An Investigation Has Commenced on Behalf of Moderna, Inc. Shareholders. Contact Levi & Korsinsky to Discuss your MRNA Losses
NEW YORK, NY / ACCESSWIRE / June 28, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Moderna, Inc. ("Moderna") (NASDAQ:MRNA) concerning possible violations of federal securities laws. Moderna issued a press release "announc[ing] that the U.S. Food and Drug Administration (FDA) has approved mRESVIA (mRNA-1345), an mRNA respiratory syncytial virus (RSV) vaccine, to protect adults aged 60 years and older from lower respiratory tract disease caused by RSV infection.
Moderna (MRNA) Shares Decline on RSV Vaccine Efficacy Data
Moderna (MRNA) stock sinks after new data shows the efficacy of its mRNA-based RSV vaccine fell sharply in the second year and was lower than that of rival vaccines marketed by GSK and Pfizer.
2 Stocks Down More Than 30% to Buy Right Now
Moderna recently won approval for a second product -- one with a $10 billion market. Pfizer offers a juicy dividend yield and better growth prospects than you might think.
ATTENTION Moderna, Inc. Investors: You May Have Been Affected by Fraud - Contact Levi & Korsinsky to Discuss Your Rights
NEW YORK, NY / ACCESSWIRE / June 26, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Moderna, Inc. ("Moderna") (NASDAQ:MRNA) concerning possible violations of federal securities laws. Moderna issued a press release "announc[ing] that the U.S. Food and Drug Administration (FDA) has approved mRESVIA (mRNA-1345), an mRNA respiratory syncytial virus (RSV) vaccine, to protect adults aged 60 years and older from lower respiratory tract disease caused by RSV infection.
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Moderna, Inc. - MRNA
NEW YORK, NY / ACCESSWIRE / June 26, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Moderna, Inc. ("Moderna" or the "Company") (NASDAQ:MRNA). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Why Is Moderna Stock Trading Lower On Wednesday?
The Centers for Disease Control and Prevention's Advisory Committee on Immunization Practice will meet this week to consider and recommend who should get respiratory syncytial virus (RSV), influenza, and COVID-19 vaccines.
Moderna's stock falls after data shows biotech's RSV vaccine trails rivals after 18 months
Moderna Inc.'s stock fell 6.4% Wednesday, after the company said that its respiratory syncytial virus, or RSV, shot showed 50% efficacy in preventing the illness after 18 months.
Moderna says its RSV shot is 50% effective across a second season
Moderna Inc respiratory syncytial virus (RSV) shot mRESVIA showed 50% efficacy in preventing RSV after 18 months, the drugmaker said on Wednesday.
Moderna (MRNA) Surpasses Market Returns: Some Facts Worth Knowing
Moderna (MRNA) closed at $137.60 in the latest trading session, marking a +0.44% move from the prior day.
Moderna, Inc. (MRNA) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings
NEW YORK, NY / ACCESSWIRE / June 18, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Moderna, Inc. ("Moderna" or "the Company") (NASDAQ:MRNA). Investors who purchased Moderna securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/MRNA.
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Moderna, Inc. - MRNA
NEW YORK, NY / ACCESSWIRE / June 17, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Moderna, Inc. ("Moderna" or the "Company") (NASDAQ:MRNA). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
